Scientists assessed proof-of-mechanism and clinical feasibility for Sacituzumab govitecan (SG) and talazoparib employing an innovative sequential dosing schedule. In vitro, sequential SG followed by talazoparib delayed topoisomerase 1 cleavage complex clearance, increased DNA damage and promoted apoptosis.
[Clinical Cancer Research]
